Siren L.L.C. Purchases 2,486,997 Shares of Erasca, Inc. $ERAS

Siren L.L.C. grew its position in shares of Erasca, Inc. (NASDAQ:ERAS) by 28.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,244,246 shares of the company’s stock after purchasing an additional 2,486,997 shares during the quarter. Erasca makes up about 5.0% of Siren L.L.C.’s portfolio, making the stock its 3rd biggest holding. Siren L.L.C.’s holdings in Erasca were worth $181,932,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in ERAS. BNP Paribas Financial Markets grew its position in Erasca by 58.0% during the second quarter. BNP Paribas Financial Markets now owns 21,579 shares of the company’s stock valued at $27,000 after buying an additional 7,923 shares during the period. EP Wealth Advisors LLC acquired a new position in shares of Erasca in the second quarter worth about $29,000. Russell Investments Group Ltd. acquired a new position in shares of Erasca in the third quarter worth about $31,000. EntryPoint Capital LLC purchased a new stake in shares of Erasca during the 4th quarter worth about $38,000. Finally, Stifel Financial Corp purchased a new stake in shares of Erasca during the 4th quarter worth about $38,000. 67.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ERAS has been the subject of several recent analyst reports. Morgan Stanley lifted their price target on Erasca from $12.00 to $21.00 and gave the company an “equal weight” rating in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Erasca in a research report on Thursday, June 11th. HC Wainwright reissued a “buy” rating on shares of Erasca in a report on Tuesday, July 14th. Mizuho cut their price objective on Erasca from $28.00 to $26.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th. Finally, Wolfe Research set a $16.00 target price on Erasca in a research note on Thursday, June 4th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $21.64.

Trending Headlines about Erasca

Here are the key news stories impacting Erasca this week:

• Neutral Sentiment: Several law firms issued reminders about the ongoing class action against Erasca and the approaching August 10 lead-plaintiff deadline, keeping legal overhang front and center for investors. Article: ROSEN, A LONGSTANDING FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS
• Neutral Sentiment: The lawsuit alleges Erasca and certain executives violated federal securities laws by making misleading statements about its lead oncology candidate, ERAS-0015, including claims tied to competitive advantage, safety, and intellectual property protection. Article: ERAS INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit – HBSS
• Neutral Sentiment: One update also highlighted claims that investors lost about $11.59 per share after “corrective disclosures” in late April 2026, reinforcing the narrative that prior expectations around the drug program may have been too optimistic. Article: Lost Money on Erasca, Inc. (ERAS)? Join Class Action Suit Seeking Recovery – Contact SueWallSt

Erasca Stock Down 0.9%

Shares of NASDAQ ERAS opened at $19.34 on Friday. The firm has a market cap of $6.01 billion, a price-to-earnings ratio of -20.80 and a beta of 0.66. The company’s 50-day simple moving average is $15.26 and its 200-day simple moving average is $13.88. Erasca, Inc. has a 52-week low of $1.33 and a 52-week high of $24.28.

Erasca (NASDAQ:ERAS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). Equities research analysts anticipate that Erasca, Inc. will post -0.54 EPS for the current fiscal year.

Erasca Company Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.